In summary, based on our interdisciplinary approach, we screened the ChemBridge database and predicted CB-006-3 as a dual inhibitor that can selectively target PI3KCG, PI3KCD subunits of PI3K and BRAFV600E mutant kinase to effectively act against melanoma cell proliferations via apoptotic induction. This evidence concerns the gene PIK3CG and melanoma.